We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Devicemakers can request an exemption to submit adverse event data from real-world data (RWD) sources in formats other than the FDA’s electronic reporting format, the agency said in an update of its web page on medical device report (MDR) exception requests.
The FDA has updated its Recognized Consensus Standards database, known as “List 59,” with several new standards as well as revisions to three existing standards.
The FDA started the year with a soft launch of its Total Product Life Cycle Advisory Program (TAP) pilot, with the intention of enrolling up to 15 devices in fiscal 2023.
Pediatric use of medical devices “requires considerations such as growth and development, anatomical and physiological differences, hormonal influences, and activity level,” the NCC-PDI says.
While the FDA regulates medical devices, it shares oversight of how devices are promoted with the Federal Trade Commission (FTC). This oversight extends to social media, where many companies find avenues for product promotion — and various ways in which advertising can go afoul of the law.
The National Capital Consortium for Pediatric Device Innovation (NCC-PDI) and the Children’s National Hospital are inviting applications from manufacturers with already-cleared devices to use real world evidence (RWE) to gain FDA clearance for pediatric use.
The FDA has granted Class II designations — with general or special controls to assure safety — for several categories of devices submitted to the agency through the De Novo review pathway.
The proposed European Artificial Intelligence Act (AIA) will impose an additional burden on the already limited number of notified bodies, resulting in delays in the marketing of new medical devices and technologies, the European Association of Medical Devices Notified Bodies (Team-NB) says.
Advanced Bionics has agreed to pay more than $12 million to resolve allegations that it made false claims in premarket approval applications (PMAs) for some of its cochlear implant processors, the Department of Justice said.